Induction in the ALLG NBCR cohort utilized idarubicin as the main anthracycline as part of a 7 + 3 (35%) or high-dose cytarabine-based (65%) induction regimen, with both induction approaches delivering similar OS outcomes in FLT3 mutated AML (Fig. 1A). Here, FLT3 is linked to acute myeloid leukemia.